Autoantibodies Targeting Nephrin in Podocytopathies.
Hengel FE, Dehde S, Lassé M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F, Lucas R, Mehner LM, Zimmermann T, Billing AM, Oh J, Mitrotti A, Pontrelli P, Debiec H, Dossier C, Colucci M, Emma F, Smoyer WE, Weins A, Schaefer F, Alachkar N, Diemert A, Hogan J, Hoxha E, Wiech T, Rinschen MM, Ronco P, Vivarelli M, Gesualdo L, Tomas NM, Huber TB; International Society of Glomerular Disease.
N Engl J Med. 2024 Aug 1;391(5):422-433. doi: 10.1056/NEJMoa2314471. Epub 2024 May 25.
Primary glomerulonephritides.
Floege J, Amann K.
Lancet. 2016 May 14;387(10032):2036-48. doi: 10.1016/S0140-6736(16)00272-5. Epub 2016 Feb 25.
Advances in primary glomerulonephritis.
Ellison B, Cader R, Willcocks L.
Br J Hosp Med (Lond). 2024 Jul 30;85(7):1-11. doi: 10.12968/hmed.2024.0044.
Treatment of IgA Nephropathy: A Rapidly Evolving Field.
El Karoui K, Fervenza FC, De Vriese AS.
J Am Soc Nephrol. 2024 Jan 1;35(1):103-116. doi: 10.1681/ASN.0000000000000242. Epub 2023 Sep 29.
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants.
Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22.
Sparsentan: First Approval.
Syed YY.
Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.
Shining a LAMP on pauci-immune focal segmental glomerulonephritis.
Salama AD, Pusey CD.
Kidney Int. 2009 Jul;76(1):15-7. doi: 10.1038/ki.2009.123. Epub 2009 Apr 22.
[A new variant of IgA mesangial deposit glomerulonephritis with focal-segmental sclerosis and an anomalous clinical picture].
Monga G.
Pathologica. 1997 Oct;89(5):568-9.
Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Elnaga AAA, Alsaied MA, Elettreby AM, Ramadan A, Abouzid M, Shetta R, Al-Ajlouni YA.
BMC Nephrol. 2024 Sep 27;25(1):316. doi: 10.1186/s12882-024-03713-9.
Clinical significance of focal segmental glomerulosclerosis subclassification in IgA nephropathy.
Lu F, Hou S, Liu C, Li Q, Wu L, Pan Y, Wu Y, Shu H, Zhang B, Mao H, Li T, Xing C, Duan S, Yuan Y.
Nephrol Dial Transplant. 2026 Jan 30;41(2):297-308. doi: 10.1093/ndt/gfaf162.
